Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study.

医学 化疗 内科学 多西紫杉醇 肿瘤科 临床终点 中期分析 临床研究阶段 化疗方案 随机对照试验 临床试验 吉西他滨 拓扑异构酶 临时的 外科 癌症 中止 联合化疗 胃肠病学
作者
Z T Lu,Zhangzhou Huang,Xiangjiao Meng,Yun Fan,Tao Wu,Qingsong Pang,Fang Wang,Yanqiao Zhang,Shegan Gao,Tianshu Liu,Jin Zhou,Yong Fang,Ning Li,Wei Li,Guochun Cao,Sa Xiao,Hai Zhu,Yi Zhu,Lin Shen
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (16_suppl): 4008-4008 被引量:5
标识
DOI:10.1200/jco.2026.44.16_suppl.4008
摘要

4008 Background: Chemotherapy plus a PD-1/PD-L1 inhibitor is the standard first-line treatment for PD-L1 expressing advanced ESCC. However, most patients (pts) inevitably develop resistance to first-line therapy, and second-line chemotherapy shows an ORR of less than 10% and a median OS of less than 6 mo, highlighting the urgent need for novel therapeutics. Iza-bren is a potentially first-in-class ADC consisting of an EGFR-HER3 bispecific antibody conjugated to a potent topoisomerase I inhibitor Ed-04 via a cleavable linker. Iza-bren has shown promising clinical activity in previously treated ESCC pts in phase I study. Here, we present results from a phase III, randomized, open-label, multicenter study conducted in China evaluating the efficacy and safety of iza-bren versus chemotherapy as second line treatment for advanced ESCC. Methods: Pts with recurrent or metastatic ESCC who had progressed after first-line treatment with a PD-1/PD-L1 inhibitor plus platinum-based chemotherapy were randomized (1:1) to receive iza-bren (2.5 mg/kg at D1D8 Q3W) or physician’s choice of chemotherapy (irinotecan, paclitaxel, or docetaxel Q3W). Dual primary endpoints were OS and PFS by Blinded Independent Central Review (BICR) per RECIST v1.1. Results: As of Oct 17, 2025, a total of 497 pts were randomized to iza-bren (n = 249) or chemotherapy (n = 248). Baseline characteristics were balanced between the two groups. At interim analysis, median follow-up for OS was 7.8 mo in the iza-bren group and 7.6 mo in the chemotherapy group. Iza-bren has demonstrated statistically significant and clinically meaningful improvement in both OS and PFS by BICR compared with chemotherapy. The median OS was 9.8 mo (95% CI, 7.9 to 11.0) with iza-bren and 7.2 mo (95% CI, 6.2 to 8.2) with chemotherapy (HR, 0.64; 95% CI, 0.49 to 0.83; P = 0.0004). The median PFS by BICR was 4.2 mo (95% CI, 3.6 to 4.5) with iza-bren and 2.0 mo (95% CI, 1.6 to 2.7) with chemotherapy (HR, 0.50; 95% CI, 0.40 to 0.63; P < 0.0001). ORR by BICR was 35.3% for iza-bren and 13.1% for chemotherapy. Grade≥3 TRAEs, which were predominantly hematologic in nature, occurred in 85.1% in the iza-bren group and 60.2% in the chemotherapy group. TRAEs leading to drug discontinuation were 2.0% in the iza-bren group and 3.3% in the chemotherapy group. TRAEs leading to death were 1.2% in the iza-bren group and 1.6% in the chemotherapy group. Conclusions: The study met both dual primary endpoints at prespecified interim analysis. Iza-bren demonstrated statistically significant and clinically meaningful improvements in OS and PFS compared with chemotherapy in pts with recurrent or metastatic ESCC who had progressed after first line PD-1/PD-L1 inhibitor plus platinum-based chemotherapy. The safety profile was manageable. The results support iza-bren as a new second-line standard of care for ESCC. Clinical trial information: NCT06304974 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
他山之鱼发布了新的文献求助10
1秒前
1秒前
柒柒止步完成签到 ,获得积分10
1秒前
无花果的应助被sai采纳,获得10
2秒前
111发布了新的文献求助10
2秒前
曼曼完成签到,获得积分10
2秒前
科研通AI2S的应助被Hasson采纳,获得10
2秒前
JDK完成签到,获得积分10
2秒前
大个的应助被XIN采纳,获得10
3秒前
烟花的应助被嘻嘻嘻采纳,获得10
3秒前
Lotus发布了新的文献求助10
4秒前
欢喜的迎丝完成签到 ,获得积分10
4秒前
危机的觅风完成签到,获得积分10
5秒前
Mxr关闭了Mxr的文献求助
5秒前
ZeKaWa的应助被louis采纳,获得10
5秒前
大仙完成签到,获得积分10
6秒前
6秒前
dada发布了新的文献求助10
7秒前
7秒前
苦瓜大王完成签到,获得积分10
7秒前
7秒前
7秒前
单纯如柏发布了新的文献求助10
7秒前
mengxiang完成签到,获得积分20
8秒前
8秒前
QDU的应助被刻苦的幻巧采纳,获得20
8秒前
李健的应助被科研通管家采纳,获得10
8秒前
英姑的应助被科研通管家采纳,获得10
8秒前
Jasper的应助被科研通管家采纳,获得10
9秒前
Owen的应助被科研通管家采纳,获得10
9秒前
丘比特的应助被科研通管家采纳,获得50
9秒前
科研通AI65的应助被xh采纳,获得10
9秒前
酷波er的应助被科研通管家采纳,获得10
9秒前
小二郎的应助被科研通管家采纳,获得10
9秒前
9秒前
Maestro_S的应助被科研通管家采纳,获得10
9秒前
CipherSage的应助被Firsterchao采纳,获得30
9秒前
9秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175707
求助须知:如何正确求助?哪些是违规求助? 9567353
关于积分的说明 21792214
捐赠科研通 7770334
什么是DOI,文献DOI怎么找? 3431908
关于科研通互助平台的介绍 2556260
邀请新用户注册赠送积分活动 2477417